TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34883524

Group type: EXPERIMENTAL
Intervention: Standard medical care + telemonitoring device
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Telemetry use
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Coronary heart disease presence
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hypertension presence
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patient's body mass
Number of subjects: 60
Study: 36229973

Group type: EXPERIMENTAL
Intervention: Safety guidewire (SGW)
Number of subjects: 348

Group type: COMPARATOR
Intervention: No safety guidewire (NSGW)
Number of subjects: 348
Study: 32868858

Group type: EXPERIMENTAL
Intervention: Lactose-free infant formula (Similac Sensitive®)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Lactose-containing infant formula (Similac Advance®)
Number of subjects: 74
Study: 32502923

Group type: EXPERIMENTAL
Intervention: SB8
Number of subjects: 763
Study: 34667103

Group type: EXPERIMENTAL
Intervention: DSP with memory aids
Number of subjects: 469

Group type: COMPARATOR
Intervention: Usual care plus existing dementia guide
Number of subjects: 469
Study: 33677430

Group type: EXPERIMENTAL
Intervention: Peer support approach (3 groups, n = 51)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (3 groups, n = 52)
Number of subjects: 103
Study: 36193841

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 214

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 214
Study: 32569414

Group type: EXPERIMENTAL
Intervention: Parallel neurotomy
Number of subjects: 43

Group type: COMPARATOR
Intervention: Perpendicular neurotomy
Number of subjects: 43
Study: 36099211

Group type: EXPERIMENTAL
Intervention: Pegloticase + Methotrexate (MTX)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Pegloticase + Placebo (PBO)
Number of subjects: 152
Study: 34487875

Group type: COMPARATOR
Intervention: Conventional Etch and Rinse + MC (Control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CP + BA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MBP + BA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MBP + MC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CP + MC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study: 35412472

Group type: EXPERIMENTAL
Intervention: Early Mobilization + Neuromuscular Electrical Stimulation (EM+NMES)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Early Mobilization (EM)
Number of subjects: 139
Study: 33091332

Group type: EXPERIMENTAL
Intervention: Prognostic nomogram for predicting overall survival (OS)
Number of subjects: 1822

Group type: EXPERIMENTAL
Intervention: Prognostic nomogram for predicting cancer-specific survival (CSS)
Number of subjects: 1822
Study: 32326082

Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation (MM)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Physical Exercise (PE)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 94
Study: 34789618

Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Mepivacaine
Number of subjects: 28
Study: 34755014

Group type: EXPERIMENTAL
Intervention: Laparoscopic colectomy (LAP)
Number of subjects: 1028

Group type: COMPARATOR
Intervention: Open colectomy (OP)
Number of subjects: 1028
Study: 35477351

Group type: EXPERIMENTAL
Intervention: Sonlicromanol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 33464392

Group type: EXPERIMENTAL
Intervention: COBRA therapy (methotrexate 7.5 mg/week, sulfasalazine 2 g/day plus initially prednisolone 60 mg/day)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: COBRA-light therapy (methotrexate 25 mg/week plus initially prednisolone 30 mg/day)
Number of subjects: 155
Study: 33159283

Group type: EXPERIMENTAL
Intervention: Gel applied on the mask edge
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard mask ventilation without gel
Number of subjects: 74
Study: 32611224

Group type: EXPERIMENTAL
Intervention: Cancer Home‐Life Intervention
Number of subjects: 113
Study: 33876666

Group type: EXPERIMENTAL
Intervention: Lower social support
Number of subjects: 4507

Group type: EXPERIMENTAL
Intervention: Lower scores on social autonomy
Number of subjects: 4507

Group type: EXPERIMENTAL
Intervention: Increased suicidality risk score
Number of subjects: 4507

Group type: EXPERIMENTAL
Intervention: Lower scores on psychosocial functioning
Number of subjects: 4507
Study: 32199523

Group type: EXPERIMENTAL
Intervention: HPD alone (1.5 to 2.2 g/kg/day protein)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: HPD plus multistrain probiotic formulation
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: HPD plus prebiotic (5.6 g inulin)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: HPD plus synbiotic (probiotic plus inulin)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: HPD (all variations)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 26
Study: 36195460

Group type: EXPERIMENTAL
Intervention: High-quality shared toilets (users contributed 10%-15% of capital cost)
Number of subjects: 424

Group type: COMPARATOR
Intervention: Low-quality pit latrines (control group)
Number of subjects: 424
Study: 33932507

Group type: EXPERIMENTAL
Intervention: Trabectedin 1.5 mg/m2 every 3 weeks
Number of subjects: 103

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 103
Study: 32441407

Group type: EXPERIMENTAL
Intervention: Cement-retained abutment (n = 24)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Titanium base (n = 28)
Number of subjects: 21
Study: 34052081

Group type: EXPERIMENTAL
Intervention: Popliteal-sciatic nerve block with 0.5% Bupivacaine (0.25 ml/kg) in Group 2A (ages 7–15)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Local surgical site infiltration with 0.5% Bupivacaine (0.25 ml/kg) in Group 2B (ages 7–15)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Popliteal-sciatic nerve block with 0.5% Bupivacaine (0.25 ml/kg) in Group 1A (ages 1–6)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Local surgical site infiltration with 0.5% Bupivacaine (0.25 ml/kg) in Group 1B (ages 1–6)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Popliteal-sciatic nerve block in Group 2A (ages 7–15)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Local surgical site infiltration in Group 2B (ages 7–15)
Number of subjects: 40
Study: 32680875

Group type: EXPERIMENTAL
Intervention: Aspiration thrombectomy
Number of subjects: 165

Group type: COMPARATOR
Intervention: Stent retriever thrombectomy
Number of subjects: 165
Study: 35039260

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate combined with rhEGF eye drops
Number of subjects: 97

Group type: COMPARATOR
Intervention: Sodium hyaluronate eye drops
Number of subjects: 97
Study: 33739487

Group type: EXPERIMENTAL
Intervention: Interventional nursing management including continuous epitympanic temperature monitoring, early installation in a heated ambulance (temperature target >30°C), protection by a survival blanket, and use of heated solutes (temperature objective >35°C).
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Conventional management (control group).
Number of subjects: 1200
Study: 32969833

Group type: EXPERIMENTAL
Intervention: BBL‐GP (web‐based intervention augmented with an in‐person diet and physical activity consultation)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: LMP (single clinician‐led group, Lifestyle Modification Program)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control (web‐based control)
Number of subjects: 125
Study: 36026525

Group type: EXPERIMENTAL
Intervention: Continuous AG training (1×30 min/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intermittent AG training (6 × 5 min/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no AG training)
Number of subjects: 24
Study: 33277091

Group type: EXPERIMENTAL
Intervention: 1 mcg/kg dexmedetomidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.03 mg/kg midazolam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 36463433

Group type: EXPERIMENTAL
Intervention: Modified Peyton teaching approach (G1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional teaching method (watching a teaching video for 30 min) (G2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 32011723

Group type: EXPERIMENTAL
Intervention: Kerala Diabetes Prevention Program (K-DPP) intervention delivered by peer leaders over 12 months.
Number of subjects: 375000
Study: 36006668

Group type: EXPERIMENTAL
Intervention: Headspace (unguided digital mindfulness-based self-help app)
Number of subjects: 2182

Group type: EXPERIMENTAL
Intervention: Headspace
Number of subjects: 2182

Group type: COMPARATOR
Intervention: Moodzone (active control)
Number of subjects: 2182
Study: 34474011

Group type: EXPERIMENTAL
Intervention: ? blockers in sinus rhythm (n=12,822)
Number of subjects: 15659

Group type: EXPERIMENTAL
Intervention: ? blockers in atrial fibrillation (n=2837)
Number of subjects: 15659

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15659
Study: 32768331

Group type: EXPERIMENTAL
Intervention: Yang Yan Qing E Wan (YYQEW)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Model group (H2O2 treatment)
Number of subjects: 0
Study: 35487141

Group type: EXPERIMENTAL
Intervention: Open-label placebo with treatment rationale (OLP+)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Open-label placebo without treatment rationale (OLP-)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No pill control (NPC)
Number of subjects: 45
Study: 33905555

Group type: EXPERIMENTAL
Intervention: Neoadjuvant docetaxel and androgen deprivation therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no neoadjuvant therapy)
Number of subjects: 100
Study: 34428112

Group type: EXPERIMENTAL
Intervention: Liq HRV
Number of subjects: 451

Group type: COMPARATOR
Intervention: Lyo HRV
Number of subjects: 451
Study: 36350392

Group type: EXPERIMENTAL
Intervention: Augmented Reality Ultrasound (AR US)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard Ultrasound (sUS)
Number of subjects: 44
Study: 32877884

Group type: EXPERIMENTAL
Intervention: LigaSure
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional IFL (sharp/diathermia)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 20
Study: 36273179

Group type: EXPERIMENTAL
Intervention: Simulation scenarios with varying levels of interaction effects
Number of subjects: 3278

Group type: EXPERIMENTAL
Intervention: Simulation scenarios with no 'true' intervention effect
Number of subjects: 3278

Group type: EXPERIMENTAL
Intervention: Simulation scenarios with 'true' intervention effects
Number of subjects: 3278

Group type: EXPERIMENTAL
Intervention: Sample size adjustments
Number of subjects: 3278
Study: 33755674

Group type: EXPERIMENTAL
Intervention: Strontium-90 brachytherapy (15-20Gy)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone and 5-fluorouracil injections
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no adjuvant treatment)
Number of subjects: 31
Study: 35428979

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (>60 seconds or when the cord stopped pulsing)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Immediate cord clamping (within 15 seconds after birth)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 122
Study: 32659482

Group type: EXPERIMENTAL
Intervention: Transcranial random noise stimulation (tRNS) + DC-offset
Number of subjects: 49

Group type: COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 49
Study: 34918332

Group type: EXPERIMENTAL
Intervention: Resveratrol treatment (150 mg/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 8
Study: 32942043

Group type: EXPERIMENTAL
Intervention: Zibotentan (10 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37409840

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 1 µg kg ‐1 and midazolam 0.12 mg kg ‐1 (DM group)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 1 µg kg ‐1 and ketamine 2 mg kg ‐1 (DK group)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam 0.12 mg kg ‐1 and ketamine 2 mg kg ‐1 (MK group)
Number of subjects: 150

Group type: COMPARATOR
Intervention: All groups (DM, DK, MK)
Number of subjects: 150
Study: 33422612

Group type: EXPERIMENTAL
Intervention: 24 Gy SDRT
Number of subjects: 117

Group type: COMPARATOR
Intervention: 3 × 9 Gy SBRT
Number of subjects: 117
Study: 32791411

Group type: EXPERIMENTAL
Intervention: 25% Composted Rice Straw (CRS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50% Composted Rice Straw (CRS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (CK) - 50% peat with 50% perlite
Number of subjects: 0
Study: 36163930

Group type: EXPERIMENTAL
Intervention: Asciminib 80mg QD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asciminib 40mg BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asciminib 200mg BID
Number of subjects: 0
Study: 34137308

Group type: EXPERIMENTAL
Intervention: Group-based prenatal exercise program
Number of subjects: 21
Study: 32285126

Group type: EXPERIMENTAL
Intervention: Oral cedazuridine/decitabine (100 mg/35 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: IV decitabine (20 mg/m2)
Number of subjects: 80
Study: 35321792

Group type: EXPERIMENTAL
Intervention: Combination of preformed titanium plates and optimized 3D digital surgical guide plates (Group A)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Preformed titanium plates only (Group B)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional treatment (Group C)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Group A (optimized 3D digital surgical guide plates)
Number of subjects: 26
Study: 34540641

Group type: EXPERIMENTAL
Intervention: Restrictive fluid management (RG) with infusion of Ringer’s lactate at a rate of 3 mL/kg/h
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional fluid management (CG) with Ringer’s lactate at conventional calculated doses
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Restrictive fluid management (RG)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional fluid management (CG)
Number of subjects: 80
Study: 32636099

Group type: EXPERIMENTAL
Intervention: Urethroplasty
Number of subjects: 222

Group type: COMPARATOR
Intervention: Urethrotomy
Number of subjects: 222
Study: 35157498

Group type: EXPERIMENTAL
Intervention: Antiracism intervention (real-time warning system, race-specific feedback, patient navigation)
Number of subjects: 2363

Group type: COMPARATOR
Intervention: Retrospective control group
Number of subjects: 2363

Group type: COMPARATOR
Intervention: Concurrent control group
Number of subjects: 2363

Group type: EXPERIMENTAL
Intervention: Antiracism intervention
Number of subjects: 2363
Study: 33107596

Group type: EXPERIMENTAL
Intervention: AgP+CS/EMD
Number of subjects: 60

Group type: COMPARATOR
Intervention: AgP+CS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CP+CS/EMD
Number of subjects: 60

Group type: COMPARATOR
Intervention: All groups (AgP+CS, AgP+CS/EMD, CP+CS/EMD)
Number of subjects: 60
Study: 35057774

Group type: EXPERIMENTAL
Intervention: Happy Lessons (HL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 0
Study: 32416055

Group type: EXPERIMENTAL
Intervention: Erlotinib hydrochloride test formulation (150 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Erlotinib hydrochloride reference formulation (150 mg)
Number of subjects: 0
Study: 34153269

Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 3725

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3725
Study: 32359104

Group type: EXPERIMENTAL
Intervention: nalmefene 20 mg
Number of subjects: 0
Study: 35309166

Group type: EXPERIMENTAL
Intervention: COVID-19-modified training (CMT)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Small-sided games (SSG)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Simulated match-play (SMP)
Number of subjects: 213
Study: 34027702

Group type: EXPERIMENTAL
Intervention: Complementary alternative medicine (CAM)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (carrier only)
Number of subjects: 57
Study: 35633810

Group type: EXPERIMENTAL
Intervention: ECOSA (Eating and Control Styles Axis) used during mentalisation-based psychotherapy
Number of subjects: 94

Group type: COMPARATOR
Intervention: Mentalisation-based psychotherapy (control group)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: ECOSA usage
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Correlation with EDE-Q score in the intervention group
Number of subjects: 94
Study: 33438313

Group type: EXPERIMENTAL
Intervention: Uterine cleaning
Number of subjects: 648

Group type: COMPARATOR
Intervention: No cleaning
Number of subjects: 648
Study: 35314794

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 62
Study: 36376887

Group type: EXPERIMENTAL
Intervention: Betaine 100 mg/kg/day
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Betaine 250 mg/kg/day
Number of subjects: 11
Study: 32251641

Group type: EXPERIMENTAL
Intervention: 15 μg P2-VP8 vaccine
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: 30 μg P2-VP8 vaccine
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: 90 μg P2-VP8 vaccine
Number of subjects: 617

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 617
Study: 35829751

Group type: EXPERIMENTAL
Intervention: Peak heart rate prediction equation based on resting HR, presence of diabetes, physical dysfunction (gait speed < 1.0 m/s), and hypoalbuminemia (< 3.5 g/dL)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Aerobic exercise based on estimated peak HR < 85%
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Measured peak HR values
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: HR at anaerobic threshold (AT)
Number of subjects: 126
Study: 32097165

Group type: EXPERIMENTAL
Intervention: Elective anterior resection surgery
Number of subjects: 132
Study: 35351443

Group type: EXPERIMENTAL
Intervention: Digital person‐centered care training intervention with virtual coaching
Number of subjects: 175

Group type: COMPARATOR
Intervention: Digital training program alone
Number of subjects: 175
Study: 33705168

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (Coping Cat)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Medication (sertraline)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Combination of Cognitive Behavioral Therapy and Medication
Number of subjects: 488

Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 488
Study: 32609171

Group type: EXPERIMENTAL
Intervention: Predictive Mean Matching (PMM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hot deck
Number of subjects: 0
Study: 36087316

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 139
Study: 32956756

Group type: EXPERIMENTAL
Intervention: Mepolizumab (300 mg subcutaneously every 4 weeks for 32 weeks)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo (subcutaneously every 4 weeks for 32 weeks)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 36416598

Group type: EXPERIMENTAL
Intervention: Single Bond Universal (SBU) in self-etch mode (SE)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: OptiBond Universal (OPU) in self-etch mode (SE)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Clearfil Universal Bond Quick (CBQ) in self-etch mode (SE)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Universal adhesives in etch-and-rinse mode (ER)
Number of subjects: 96
Study: 33999939

Group type: EXPERIMENTAL
Intervention: 500 mg.kg‐1 BM sodium citrate ingested over 15 min
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 500 mg.kg‐1 BM sodium citrate ingested over 30 min
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 500 mg.kg‐1 BM sodium citrate ingested over 45 min
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 500 mg.kg‐1 BM sodium citrate ingested over 60 min
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 16
Study: 35303390

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM)
Number of subjects: 75
Study: 33887652

Group type: EXPERIMENTAL
Intervention: Direct gaze directed at the observer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dynamic stimuli where gaze appeared to move toward the participant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimuli showing a full face, eye region, inverted faces, and high-contrast eye-like stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: Static pictures of full faces and dynamic nonfigurative stimuli
Number of subjects: 0
Study: 34508582

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 594

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 594
Study: 32506504

Group type: EXPERIMENTAL
Intervention: EAM‐ICE (zero-fluoroscopy)
Number of subjects: 57

Group type: COMPARATOR
Intervention: F‐ICE (fluoroscopy)
Number of subjects: 57
Study: 36428016

Group type: EXPERIMENTAL
Intervention: Heated, humidified, high-flow nasal cannula oxygen postextubation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (treatment at the discretion of the treating provider)
Number of subjects: 0
Study: 34463538

Group type: EXPERIMENTAL
Intervention: Pharmacist-led interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 35760117

Group type: EXPERIMENTAL
Intervention: 20% Intralipid
Number of subjects: 12
Study: 32037737

Group type: EXPERIMENTAL
Intervention: Cedar fragrance (aroma extracts from cedar) added to disinfecting ethanol, administered for 8 weeks.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ethanol without added aroma extracts (control group), administered for 8 weeks.
Number of subjects: 36